Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
21.07
-0.17 (-0.80%)
At close: Jan 6, 2025, 4:00 PM
21.05
-0.02 (-0.10%)
After-hours: Jan 6, 2025, 7:59 PM EST
Teva Pharmaceutical Revenue
Teva Pharmaceutical had revenue of $4.33B in the quarter ending September 30, 2024, with 12.52% growth. This brings the company's revenue in the last twelve months to $16.77B, up 9.81% year-over-year. In the year 2023, Teva Pharmaceutical had annual revenue of $15.85B with 6.17% growth.
Revenue (ttm)
$16.77B
Revenue Growth
+9.81%
P/S Ratio
1.42
Revenue / Employee
$443,106
Employees
37,851
Market Cap
23.91B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
Dec 31, 2019 | 16.89B | -1.38B | -7.57% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 393.90B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
TEVA News
- 10 days ago - Duvakitug And Teva's Growth: A Game Changer In Pharma - Seeking Alpha
- 14 days ago - Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 17 days ago - Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025 - GlobeNewsWire
- 19 days ago - Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases - Benzinga
- 19 days ago - TEVA stock soars 26%: What's going on with Teva Pharmaceuticals? - Invezz
- 20 days ago - Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's - Investopedia
- 20 days ago - Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment - WSJ
- 20 days ago - Why Are Teva And Sanofi Stocks Trading Higher On Tuesday? - Benzinga